Atria Investments Inc Sells 792 Shares of Eli Lilly and Company (NYSE:LLY)

Atria Investments Inc lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,819 shares of the company's stock after selling 792 shares during the period. Eli Lilly and Company accounts for 0.5% of Atria Investments Inc's investment portfolio, making the stock its 29th largest holding. Atria Investments Inc's holdings in Eli Lilly and Company were worth $39,494,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of LLY. Principle Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 1.1% in the 1st quarter. Principle Wealth Partners LLC now owns 6,616 shares of the company's stock valued at $5,465,000 after purchasing an additional 73 shares in the last quarter. One Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 33.2% during the 1st quarter. One Wealth Advisors LLC now owns 445 shares of the company's stock valued at $368,000 after acquiring an additional 111 shares in the last quarter. Lifeworks Advisors LLC boosted its stake in shares of Eli Lilly and Company by 16.7% during the 1st quarter. Lifeworks Advisors LLC now owns 9,512 shares of the company's stock worth $7,856,000 after purchasing an additional 1,358 shares during the last quarter. Journey Strategic Wealth LLC boosted its stake in shares of Eli Lilly and Company by 15.5% during the 1st quarter. Journey Strategic Wealth LLC now owns 3,478 shares of the company's stock worth $2,872,000 after purchasing an additional 468 shares during the last quarter. Finally, Advisor OS LLC boosted its position in shares of Eli Lilly and Company by 0.3% in the first quarter. Advisor OS LLC now owns 5,361 shares of the company's stock worth $4,428,000 after acquiring an additional 18 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $6.30 during trading on Friday, reaching $811.73. 2,976,064 shares of the company traded hands, compared to its average volume of 2,810,305. The company's 50 day moving average is $771.95 and its two-hundred day moving average is $800.51. The firm has a market capitalization of $769.30 billion, a PE ratio of 66.05, a PEG ratio of 1.18 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the previous year, the company posted $2.58 earnings per share. The business's revenue was up 45.2% compared to the same quarter last year. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.74%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.